Amit Kumar - Anixa Biosciences Chairman of the Board and Presidentident, CEO
| ANIX Stock | USD 3.30 0.01 0.30% |
Chairman
Dr. Amit Kumar, Ph.D., is the Chairman of the Board, President, Chief Executive Officer of the Company. He served as our President and Chief Executive Officer since July 6, 2017, as a director of the Company since November 30, 2012 and as Executive Chairman of the Board since August 23, 2016. From June 15, 2015 until August 23, 2016, Dr. Kumar served as Vice Chairman of the Board. Dr. Kumar served as a strategic advisor to the Company since September 19, 2012. Dr. Kumar was Executive Chairman of the board of directors of Anixa Diagnostics Corporationrationration, a whollyowned subsidiary of the Company since June 15, 2015. Upon his appointment as Executive Chairman of Anixa, Dr. Kumar resigned from his position as the CEO of Geo Fossil Fuels LLC, an energy company, which he had held since December 2010. From September 2001 to June 2010, Dr. Kumar was President and CEO of CombiMatrix Corporationrationration, a NASDAQ listed biotechnology company and also served as director from September 2000 to June 2012. Dr. Kumar was Vice President of Life Sciences of Acacia Research Corporationrationration, a publicly traded investment company, from July 2000 to August 2007 and also served as a director from January 2003 to August 2007. Dr. Kumar has served as Chairman of the board of directors of Ascent Solar Technologies, Inc., a publiclyheld solar energy company, since June 2007, and as a director of Aeolus Pharmaceuticals, Inc. since June 2004. Dr. Kumar holds an A.B. in Chemistry from Occidental College and Ph.D. from Caltech and completed his postdoctoral training at Harvard University. Dr. Kumar has experience in technology driven startups, both at the board of directors and operating levels, in a broad variety of areas including finance, acquisitions, research and development, and marketing, and, as described above, has served as a director andor officer of various publicly traded companies. since 2017.
| Age | 60 |
| Tenure | 7 years |
| Address | 3150 Almaden Expressway, San Jose, CA, United States, 95118 |
| Phone | 408 708 9808 |
| Web | https://www.anixa.com |
Amit Kumar Latest Insider Activity
Tracking and analyzing the buying and selling activities of Amit Kumar against Anixa Biosciences stock is an integral part of due diligence when investing in Anixa Biosciences. Amit Kumar insider activity provides valuable insight into whether Anixa Biosciences is net buyers or sellers over its current business cycle. Note, Anixa Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Anixa Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Amit Kumar over six months ago Acquisition by Amit Kumar of 28000 shares of Anixa Biosciences at 2.11 subject to Rule 16b-3 | ||
Amit Kumar over six months ago Disposition of 1500000 shares by Amit Kumar of Anixa Biosciences subject to Rule 16b-3 | ||
Amit Kumar over six months ago Acquisition by Amit Kumar of 1000000 shares of Anixa Biosciences at 2.83 subject to Rule 16b-3 |
Anixa Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3465) % which means that it has lost $0.3465 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5524) %, meaning that it created substantial loss on money invested by shareholders. Anixa Biosciences' management efficiency ratios could be used to measure how well Anixa Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2024. Return On Capital Employed is likely to drop to -0.57 in 2024. At this time, Anixa Biosciences' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 181.4 K in 2024.Similar Executives
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Anixa Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. Anixa Biosciences (ANIX) is traded on NASDAQ Exchange in USA. It is located in 3150 Almaden Expressway, San Jose, CA, United States, 95118 and employs 4 people. Anixa Biosciences is listed under Biotechnology category by Fama And French industry classification.Management Performance
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.35 |
Anixa Biosciences Leadership Team
Elected by the shareholders, the Anixa Biosciences' board of directors comprises two types of representatives: Anixa Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anixa. The board's role is to monitor Anixa Biosciences' management team and ensure that shareholders' interests are well served. Anixa Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anixa Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amit Kumar, Chairman of the Board and Presidentident, CEO | ||
| John Roop, Senior Engineering | ||
| Pamela Garzone, Chief Officer | ||
| Thomas Schlumpberger, Ex Diagnostics |
Anixa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anixa Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 85.68 M | ||||
| Shares Outstanding | 32.18 M | ||||
| Shares Owned By Insiders | 5.05 % | ||||
| Shares Owned By Institutions | 17.40 % | ||||
| Number Of Shares Shorted | 411.56 K | ||||
| Price To Earning | (51.83) X | ||||
| Price To Book | 4.88 X | ||||
| Price To Sales | 481.54 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.